# Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

> **NCT06418061** · PHASE1 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 198 (estimated)

## Conditions studied

- Unresectable
- Locally Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** IBI3005

## Key facts

- **NCT ID:** NCT06418061
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-08
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06418061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06418061, "Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06418061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*